Drugwatcher’s New Report Sheds Light On Invokana Side Effects and Lawsuits

Apr 12, 2018

Drugwatcher has published a new report highlighting the side effects of Invokana, the lawsuits filed against it till date and is also extending professional help for Invokana consumers who are planning to file a lawsuit.

Seattle, United States - April 12, 2018 /PressCable/ —

A Type-2 diabetes drug that was initially launched as a “revolutionary medication” has been found to lead to an alarming roster of side effects.

The drug in question is “Invokana” and is manufactured by Johnson & Johnson’s subsidiary Janssen Pharmaceuticals. Leading Pharma consumer watchdog Drugwatcher has recently published an eye-opening report on its website that sheds light on the threatening side effects of the apparent wonder drug and numerous lawsuits filed against it by the traumatized consumers.

The report can be found on the website: https://www.drugwatcher.org/invokana-lawsuit/

Titled as “Invokana Lawsuit 2018”, the Drugwatcher report reveals over a thousand lawsuits are presently pending against Johnson & Johnson as of 2018. Patients who have suffered side effects have alleged that these side effects were not mentioned on the warning label of Invokana. Worse, it has also been found that the drug company’s pre-distribution trials showed evidence of many of these side effects but were not reported to the FDA.

“The FDA approved Invokana for sale in 2013 under the impression that long-term studies would be conducted to check the safety quotient of the drug. Unfortunately, most of the side effects are really severe and many patients have finally filed a lawsuit against the manufacturing company”, read the Drugwatcher’s report on Invokana.

The Drugwatcher website has discussed in detail about the dangers associated with Invokana and the painful experiences suffered by the consumers who have opted for the drug. The page also contains a video which extends information on the Invokana lawsuits and trials till date.

“Invokana has done more harm than good and has pushed its consumers to life-threatening consequences. With the number of Invokana lawsuits rising at staggering rate, we found it’s high time to warn the other consumers about the traumtic consequences of consuming this controversial drug”, stated Derek Finch, co-founder of Drugwatcher.

The inspiration behind the website stems from Mr. Finch’s tryst with the Academy Award winning biographical film “Erin Brockovich”. He was immensely moved by the story, carried an extensive research and found that nothing much has changed with the big Pharma companies’ attitude towards their consumers. Such dire circumstances pushed him to launch a neutral and informative website that will warn the public about the dangerous drugs & medical devices and also help the people in taking legal actions who have been the unfortunate victims of these products. And thus Drugwatcher was born.

“Drugwatcher is committed to help people who have suffered from the threatening consequences of drugs and defective medical devices and are clueless on where to start when they seek justice. We understand that taking a stand against a Pharma giant is a herculean task for common people and especially because the world of medical lawsuits is not exactly very transparent. We are here to support these unfortunate victims by extending a step by step expert guide in a clear language to make their road to justice easier.”

Drugwatcher is offering a free case evaluation by professionals for those planning to file a lawsuit against dangerous drugs like Invokana and defective medical devices.

Contact Info:
Name: Derek Finch
Email: info@drugwatcher.org
Organization: Drug Watcher
Address: 1601 5th Ave Suite 705, Seattle, WA 98101, United States

For more information, please visit https://www.drugwatcher.org/

Source: PressCable

Release ID: 329279

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

More News